New combo therapy shows promise for tough stomach cancers

NCT ID NCT04768686

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 25 times

Summary

This study tested a new drug (FLX475) combined with an immunotherapy (pembrolizumab) in 20 people with advanced or metastatic stomach cancer who had already tried other treatments. The goal was to see if the combination could shrink tumors. Participants were split into two groups based on whether their cancer had a certain virus (EBV) or not. The study is complete, and results will show how many patients responded to the treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, South Korea

  • Chonnam National University Hwasun Hospital

    Hwasun, Jeollanam-do, South Korea

  • Gangnam Severance Hospital

    Seoul, South Korea

  • Hanllym University Medical Center

    Anyang-si, Gyeonggi-do, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

  • The Catholic University of Korea St. Vincent Hospital

    Suwon, Gyeonggi-do, South Korea

Conditions

Explore the condition pages connected to this study.